
Katherine Cheung
390 posts

Katherine Cheung
@Katherine_Chg
PhD student in Bioethics & Health Policy at @JohnsHopkinsSPH @bermaninstitute | psychedelic ethics 🌱, research ethics




New 🚨 "Psychedelics Are Still Not Ethically Exceptional: Rebutting Recent Claims of Uniqueness" -- new work forthcoming in Neuroethics by myself, Katherine Cheung, and David Yaden. Part of a scholarly exchange with our friend and colleague Daniel Villiger. Apologies for the generic AI image from ChatGPT. LINK: researchgate.net/publication/40…








‼️New paper‼️ Does your psychedelic facilitator shape your experience? This is a key question considering that the psychedelic experience can predict treatment outcomes. We analyzed the largest dataset of its kind, featuring 20yrs+ of psilocybin trials from @JHPsychedelics


A new review in Psychiatric Times synthesizes adverse event data for psilocybin, MDMA, ketamine, and ibogaine, highlighting that risk profiles differ meaningfully across compounds and that current reporting practices remain inconsistent. Clearer differentiation at the compound level will be essential as psychedelic research and clinical access continue to expand. psychiatrictimes.com/view/adverse-e…







Have you had separate experiences with psychedelics and cannabis (i.e., a time when you experienced psychedelics and a separate time when you experienced cannabis)? If so, take our survey! Your responses help us understand these compounds better, so that we can continue to expand the science of psychedelics and knowledge about their risks and benefits. tinyurl.com/psyches-cannab…










The debate over psychological support vs psychotherapy in psychedelic treatment is confused—and that confusion matters for science, safety, and regulation. We were confused too. So we worked it through together and published what clarified it for us... 🧵


